[Retracted] Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms
Figure 1
(a) RGZ (0.1–100 M) treatment for 24, 48, and
72 hours inhibited cell growth in a dose- and time-dependent manners in
SGC-7901 gastric cancer cell line, as determined by MTT assay, which was reversed
completely by 2.5 M GW9662 pretreatment for 1 hour. Cell
viability was expressed as the percentage of cells under control conditions (0 M
of RGZ or GW9662). (b) RGZ induced apoptosis in a dose-dependent manner,
which was also reversed completely by 2.5 M GW9662 pretreatment for 1 hour. (c) RGZ treatment increased the number of
cells in the G1-G0 and decreased
the number of cells in the S phases in dose-dependent manner, which was reversed
completely by 2.5 M GW9662 pretreatment for 1 hour. Values
are the means ±SD of three representative experiments. *Statistical significance ( or
higher degree of significance) versus vehicle-treated controls.
